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Chronic pain is a major public health problem with limited treatment options. Opioids remain a routine treatment
for chronic pain, but extended exposure to opioid therapy can produce opioid tolerance and hyperalgesia. Although
the mechanisms underlying chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia remain to be
uncovered, mammalian target of rapamycin (mTOR) is involved in these disorders. The mTOR complex 1 and its
triggered protein translation are required for the initiation and maintenance of chronic pain (including cancer pain)
and opioid-induced tolerance/hyperalgesia. Given that mTOR inhibitors are FDA-approved drugs and an mTOR inhibitor is
approved for the treatment of several cancers, these findings suggest that mTOR inhibitors will likely have multiple clinical
benefits, including anticancer, antinociception/anti-cancer pain, and antitolerance/hyperalgesia. This paper compares the
role of mTOR complex 1 in chronic pain, opioid-induced tolerance, and opioid-induced hyperalgesia.
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Chronic pain and its related sequelae represent a severe
public health challenge affecting nearly 30 % of the
population [1]. In addition to its impact on quality of
life, chronic pain has an economic impact, costing over
$560 billion annually [2]. Opioids have been the main-
stay of chronic pain treatment for many decades despite
a host of shortcomings including tolerance and hyper-
algesia, which ultimately limit the efficacy of these medi-
cations [3, 4]. Tolerance is the diminishing response to
medication, requiring escalating doses to achieve the
same pain relief. Increasing the dose of opioids increases
the possibility of adverse side effects including constipa-
tion, respiratory depression, and nausea [5, 6]. Con-
versely, hyperalgesia is hypersensitivity to pain and also
can be caused by the administration of opioid medica-
tion [6]. The therapeutic limitations of opioid medica-
tions in chronic pain management show a clear need to
understand the molecular mechanisms which underpin* Correspondence: yuanxiang.tao@njms.rutgers.edu
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to pharmacologic medicine, and hyperalgesia.
Neuroplasticity in the form of adaptive changes in pro-
tein transcription and translation may contribute to the
development of chronic pain, opioid tolerance, and its
hyperalgesia [7]. Changes in the expression of neuronal
nitric oxide synthase (nNOS), protein kinase C (PKC),
CaMKIIα, and other proteins are associated with chronic
pain conditions and opioid-induced hyperalgesia or tol-
erance [8–11]. The mechanisms and signaling pathways
are still not fully understood, but mammalian target of
rapamycin (mTOR) represents a key player in the mech-
anism governing neuroplasticity in chronic pain and
opioid-induced hyperalgesia/tolerance disorders [12–21].
This paper reviews recent evidence regarding the role of
mTOR in chronic pain, opioid tolerance, and opioid-
induced hyperalgesia and discusses how mTOR partici-
pates in the development and maintenance of these
disorders. Current evidence suggests that mTOR likely
represents an excellent candidate target for novel
pharmaceutical intervention in chronic pain, opioid
tolerance, and opioid-induced hyperalgesia in patients.le distributed under the terms of the Creative Commons Attribution License
which permits unrestricted use, distribution, and reproduction in any medium,
. The Creative Commons Public Domain Dedication waiver (http://
) applies to the data made available in this article, unless otherwise stated.
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Mammalian target of rapamycin (mTOR) is a serine-
threonine protein kinase which forms 2 distinct evolution-
ary preserved protein complexes known as mTOR
complex-1 (mTORC1) and mTOR complex-2 (mTORC2)
[22, 23]. Active mTOR bound to Raptor protein forms the
rapamycin-sensitive mTORC1 complex that is predomin-
antly responsible for regulating protein translation (Fig. 1)
[24]. The mTORC1 regulates the activity of at least 4
proteins involved in protein translation via phosphoryla-
tion—4E-BP1/2, eIF4B, S6K1, S6—during the following
steps. Most mature eukaryotic mRNAs possess a 7-
methyl-guanine cap structure at the 5’-end, which controls
initiation of translation [23]. During translation initiation,
the cap structure is recognized by the eIF4G initiation
complex that includes the eIF4E protein [23]. Under basal
conditions, eIF4E remains bound to the eukaryotic initi-
ation factor 4E (eIF4E)-binding protein 1/2 (4E-BP1/2),
which prevents formation of eIF4G (Fig. 1) [25]. Active
mTOR leads to phosphorylation of 4E-BP1/2, which
changes its shape and releases eIF4E, allowing the forma-
tion of the functional eIF4G complex and initiation of
translation (Fig. 1) [23, 25]. In addition, recruitment of the
eukaryotic initiation factor 4B (eIF4B) to the initiation
complex is mTOR-dependent [26, 27]. The eIF4B needs







Fig. 1 mTOR signaling pathway. Activated mTOR phosphorylates 4E-BP1/2 an
which is then free to combine with the translation initiation complex, resultin
eIF4B and S6 which also lead to increased protein translation. 4E-BP1/2: eI
60S: an eukaryotic large ribosomal subunit. eIF4E/B/G/A: eukaryotic tran
rapamycin. p: phosphorylated. S6K1/2, p70 ribosomal S6 Kinase 1/2kinase 1/2 (S6K1/2) to associate with the translation initi-
ation complex (Fig. 1) [26, 27] and mTOR activation also
induces phosphorylation of S6K1, thereby activating it.
S6K1/2 is better known for kinase activity toward riboso-
mal S6 proteins (S6) [22, 28, 29], which are critical for
stimulating the translation rate of mRNAs containing the
5’-oligopyrimidine tract (Fig. 1). This subgroup of mRNAs
encodes primarily the proteins involved in the translation
process itself, such as all ribosomal proteins and several
elongation factors [30]. Thus, mTOR activation leads to
an increase in the translation capacity of the cell.
mTOR inhibitors in clinical use
Rapamycin, a specific inhibitor of mTOR, was discov-
ered at Easter Island (former Rapa Nui) in a bacterial
strain named Streptomyces hygroscopius [31]. Rapamycin
was first found to inhibit the growth of yeast and was
being developed as an antifungal drug [32]. Its anti-
fungal use was temporally abandoned after the discovery
of its potent immunosuppressive activity, which later
proved beneficial for transplant patients [33, 34]. The
mTOR inhibitor and some of its derivatives also showed
anti-proliferative activity which was found useful in the
treatment of certain cancers [31, 35–37]. Studies have
shown hyperactivity of mTOR in gliomas [38] as well as









d S6K1/2. The phosphorylation of 4E-BP1/2 causes the release of eIF4E
g in increased protein translation. Phosphorylated S6K1 phosphorylates
F4E-binding protein1/2. 40S: an eukaryotic small ribosomal subunit.
slation initiation factor 4E/4B/4G/4A. mTOR: mammalian target of
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activity thereby abrogating the proliferation of these can-
cers has prompted clinical trials to investigate the efficacy
of rapamycin and its analogues “Rapalogs” as novel treat-
ments in cancer therapy and their approval for specific in-
dications [34, 40, 41]. Rapamycin was recently shown to
prolong the life of mice [42], whether this effect occurs in
humans is unknown and remains to be determined.mTOR expression in pain-related regions
mTOR is expressed and distributed in pain-related central
nervous system regions. Xu et al. used immunofluores-
cence to analyze the distribution of mTOR, 4E-BP1/2,
S6K and their phosphorylated counterparts in dorsal root
ganglia (DRG) and spinal cord dorsal horn [43]. mTOR
was found in approximately 26.1 % of DRG neurons and
S6K was found in about 19.1 % of DRG neurons, with
most of small diameter [43]. 4E-BP1 was exclusively found
in DRG satellite glial cells, but it co-localized in dorsal
horn with mTOR and S6K. 4E-BP1, mTOR, and S6K are
highly expressed in the superficial dorsal horn [43]. Inter-
estingly, the activated or phosphorylated forms of these
proteins were virtually undetectable or at very low levels
under normal conditions in the DRG and dorsal
horn [43]. These findings support the behavioral observa-
tion that intrathecal administration of the mTOR inhibitor











Fig. 2 Proposed mechanism of spinal cord NMDA receptor-mediated activ
magnesium blocks NMDAR activity, thus silencing the intracellular kinases i
cancer-caused noxious insult leads to removal of the magnesium from NMD
The influx of calcium may then activate PI3K and Akt kinases which go on to
leading to protein translation initiation. 4E-BP1/2: eIF4E-binding protein1/2. Ak
NMDA receptor; NR1: a subunit of NMDA receptors. p: phosphorylated. PI3K: psuggesting that mTOR and its downstream effectors do
not play a key role in acute pain.
mTOR in chronic pain
mTOR’s role in cancer treatment is not simply limited
to its effects on neoplastic cell survival and proliferation.
Studies have shown that activation of mTOR and its
downstream effectors in spinal cord (but not in DRG)
are implicated in cancer pain [18, 44]. Shih et al. showed
that rats injected with prostate cancer cells into the
tibia, a model of bone cancer pain, experienced pain
hypersensitivity [18]. This hypersensitivity was attenu-
ated following intrathecal injection of rapamycin [18].
Rapamycin’s effect is dose-dependent without affecting
locomotor function and without significant systemic
side effects such as immunosuppression [18]. Further-
more, they showed that levels of phosphorylated mTOR
(p-mTOR) and p-S6K increased in the L4-5 dorsal horn
and DRG on the side of the prostate cancer cell injection
[18]. This increase in p-mTOR and p-S6K was blocked
in the presence of an NMDA receptor antagonist [18].
The authors proposed that the activation of NMDA
receptor-mediated spinal cord mTOR pathways contrib-
ute to the initiation, establishment, and maintenance of
bone cancer-induced pain hypersensitivity [18] (Fig. 2).
This conclusion is further supported by the observation
that NMDA receptor subunit NR1 co-localized with



















ation of mTOR signaling in cancer pain. Under normal conditions (a),
ncluding the mTOR signaling pathway. Under cancer conditions (b),
A receptors, resulting in calcium influx through NMDA receptor activation.
phosphorylate mTOR. Active mTOR phosphorylates S6K1/2 and 4E-BP1/2
t: protein kinase B. mTOR: mammalian target of rapamycin. NMDAR:
hosphoinositide 3-kinase. S6K1/2, p70 ribosomal S6 Kinase 1/2
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are involved in inflammatory pain. Liang et al. showed
that intraplantar injection of complete Freund’s adjuvant
(CFA) in a model of chronic inflammatory pain increased
the levels of p-mTOR and p-S6K1 in the ipsilateral L4/5
spinal cord and DRG [16]. Behavioral testing demonstrated
that CFA-induced mechanical and thermal pain hypersen-
sitivity could be alleviated by intrathecal administered
rapamycin [16]. Additionally, Xu et al., used λ-carrageenan
to induce persistent peripheral inflammation in rats and
found increased levels of not only p-mTOR but also up-
stream phosphorylated protein kinase B (Akt) in dorsal
horn [20]. The downstream targets of mTOR activation, p-
S6K and p-4E-BP1 were also elevated in dorsal horn [20].
More importantly, intrathecal administration of rapamycin
produced anti-nociceptive effects in this persistent inflam-
matory pain model [20]. These anti-nociceptive effects of
rapamycin were also observed in the second phase of the
formalin model [20]. Selective inhibitors of PI3K (up-
stream of Akt), Akt, or mTORC1 attenuated phase II
flinching behavior in rats that were injected with formalin
[20]. Phase II of formalin-induced inflammation is known
to represent spinal sensitization [45]. These findings dem-
onstrate the potential highly targeted role of mTOR inhibi-
tors in the treatment of inflammatory pain.
Although the mechanism of mTOR-induced inflam-
matory pain sensitivity is relatively clear, how mTOR is
involved in neuropathic pain remains elusive. Rapamycin
administration in neuropathic pain models attenuates
pain hypersensitivity in several studies in both rats and
mice [17, 18, 46]. Géranton et al. reported that spared
nerve injury (SNI)-induced mechanical allodynia was
attenuated by rapamycin delivered intrathecally 6 days
after surgery [47]. However, western blotting analysis of
dorsal horn and dorsal roots 7 days after SNI revealed
no significant changes in the expression of p-S6K [47].
Additionally, immunostaining showed no change in the
percentage of peripherin-labeled fibers expressing p-
mTOR [47]. Liang et al. also showed no change in the
basal level of p-mTOR in spinal cord and DRG after
spinal nerve ligation [16]. Conversely, Zhang et al. used
the chronic constriction injury (CCI) model of neuro-
pathic pain to analyze the role of mTOR in neuropathic
pain [21]. The phosphorylated counterparts of mTOR,
4E-BP1, and S6K were upregulated in the spinal cord
7 days and 14 days after CCI [21]. Intrathecal rapamy-
cin not only blocked this upregulation but also attenu-
ated CCI-induced mechanical allodynia (but not
thermal hyperalgesia) [21]. These data suggest that dis-
tinct types of peripheral nerve injury differentially may
regulate the activation of mTOR and its downstream ef-
fectors in spinal cord and DRG. Further research into the
mechanism of rapamycin antinociception in neuropathic
pain is required.mTOR in opioid-induced tolerance and hyperalgesia
Evidence has shown that opiate-induced tolerance and
hyperalgesia may be attributed to changes in the transcrip-
tion and translation of several key tolerance-associated
proteins including neuronal NOS, PKCγ, and CaMKIIα in
the central nervous system as well as in the peripheral
nervous system [3, 48–51]. Given that mTOR regulates
protein translation, it is reasonable to assume that mTOR
participates in the development and maintenance of
opioid-induced tolerance and hyperalgesia. Indeed, Xu et
al. used an animal model of opioid tolerance/hyperalgesia:
twice-daily intrathecal injections of 10 μg of morphine for
6 continuous days produced a time-dependent decrease in
morphine’s maximal potential analgesic effect (MPAE) at
3, 5, and 7 days post morphine injection [19]. Reductions
in mechanical threshold and thermal latency occurred
at 8 days post morphine injection [19]. Rapamycin
administered intrathecally before or after morphine
treatment blocked a decrease in morphine's MPAE, and
attenuated morphine’s effect on mechanical threshold
and thermal latency [19]. Similar to the effect of rapa-
mycin, intrathecal administration of siRNA specific for
mTOR before morphine attenuated the tolerance and
hyperalgesia [19].
Xu et al. further demonstrated that mTOR and its
downstream effectors is activated by repeated morphine
injections through the μ opioid receptor-triggered P13K/
Akt pathway in dorsal horn neurons of the spinal cord
[19]. A PI3K or Akt specific inhibitor prevented mor-
phine induced increases in the phosphorylated forms of
4E-BP1, mTOR, and S6K1 in the spinal cord. These in-
hibitors also attenuated behavioral responses observed in
the opioid-induced tolerance and hyperalgesia model
[19]. In contrast, basal pain perception and locomotor
functioning were left untouched. These findings indicate
that PI3K and Akt are involved in mTOR’s effect on
opioid-induced tolerance and hyperalgesia but not basal
pain perception and locomotor functioning.
To further uncover the mTOR-dependent mechanism
(s) of opioid-induced tolerance and hyperalgesia, Xu et al.
observed protein translation in their model of morphine-
induced tolerance [19]. Repeated morphine injections
increased nascent protein synthesis as determined by
L-azidohomoalanie. Rapamycin co-administered with
morphine diminished morphine’s increase in nascent pro-
tein synthesis. The binding of eIF4A to eIF4E, compo-
nents of the translation initiation complex, increased in
dorsal horn after repeated morphine exposure, but this in-
crease was attenuated following rapamycin co-injection.
Rapamycin also attenuated the increases of several
tolerance-associated proteins including PKCγ, nNOS,
and CaMKIIα. These findings provide a mechanism of
opioid-induced tolerance and hyperalgesia in which μ























Fig. 3 Proposed model for the involvement of spinal cord mTOR in chronic opioid tolerance and hyperalgesia. Under normal conditions (a),
mTOR is inactivated. 4E-BP1/2 binds to eIF4E, preventing its associations with the translation initiation complex, thus silencing protein translation.
After repeated morphine exposure (b), activation of μ opioid receptors leads to the phosphorylation of PI3K and Akt, initiating a phosphorylation
cascade including mTOR/S6K1/2/4E-BP1/2. eIF4E release, phosphorylated eIF4B, and phosphorylated S6 trigger protein translation. 4E-BP1/2: eIF4E-
binding protein1/2. Akt: protein kinase B. eIF4E/eIF4B, eukaryotic translation initiation factor 4E/4B. mTOR: mammalian target of rapamycin. p:
phosphorylated. PI3K: phosphoinositide 3-kinase. S6K1/2, p70 ribosomal S6 Kinase 1/2. S6K1, S6 Kinase 1. μ: μ opioid receptor
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sults in increased protein translation (Fig. 3) [19].
Conclusion
The significance of mTOR’s function in the grand
scheme of pain medicine is undisputed. mTOR is a key
puzzle piece which contributes to the understanding of
many aspects of the science of chronic pain. Numerous
potential therapeutic options exist in rapamycin and its
analogues, given mTOR’s versatility in function in many
aspects of pain mediation, cancer, and post-transplant
immunosuppression. mTOR is involved in cancer patho-
genesis, and mTOR inhibitors are currently being used
as antineoplastic agents. New data demonstrates that
mTOR shows promise as a target for chronic inflamma-
tory pain, neuropathic pain, as well as cancer pain. Re-
cent data also delivers cutting edge science tying the
vital role mTOR has in the acquisition and maintenance
of opioid tolerance/hyperalgesia. These findings prompt
us to investigate the applicability of mTOR-targeting
therapies for future treatment of a vast cadre of chronic
pain syndromes.
Summary statement
This review highlights recent findings regarding the role of
mTOR and its downstream signals in pain-related regions
after persistent inflammation, nerve injury, or repeated
opioid injections and it discusses how mTOR participatesin the development and maintenance of chronic pain and
opioid-induced tolerance and hyperalgesia.
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